Skip to content

To observe the effect of dapagliflozin on serum uric acid in Type 2 Diabetes Mellitus

To observe the effect of dapagliflozin on serum uric acid in Type 2 Diabetes Mellitus

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040135
Enrollment
Unknown
Registered
2020-11-22
Start date
2020-12-01
Completion date
Unknown
Last updated
2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Sponsors

Weishan People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. No SGLT-2i drugs have been used in the past; 2. HbA1C is less than 9% and fasting blood glucose is less than 10mmol/ L; 3. Aged 30 to 65, weight >=50kg; 4. No previous history of gout or hyperuricemia, and no uric acid-lowering medication has been used.

Exclusion criteria

Exclusion criteria: 1. Any chronic diseases such as hypertension, coronary heart disease, etc.; 2. Previous hyperuricemia is under medical treatment; 3. Gastrointestinal, liver, kidney, respiratory, cardiovascular, metabolic, immune or hormonal disorders; 4. Have had gastrointestinal surgery (except appendectomy); 5. Central nervous system disease (such as epilepsy) or mental disorders or neurological disorders; 6. Associated postural hypotension, history of dizziness or vertigo; 7. Chronic or associated acute infections; 8. History of related allergies/hypersensitivity reactions (including 1. Allergies to drugs or their excipients); 9. Long half-life drug 10 was taken for at least one month before study administration or during the trial or for less than; 10. half-lives of the corresponding drug. Participated in trials of other study drugs within 2 months prior to study administration or during the trial; 11. Drug abuse; 12. Blood donation (more than 100 mL within 4 weeks prior to study administration or during the trial); 13. Excessive physical activity (within 1 week prior to study administration or during study period); 14. Failure to follow the center's dietary regimen; 15. Baseline QT/QTc intervals were significantly longer (for example, QTc intervals were repeatedly greater than 450 ms); 16. A history of urinary and reproductive diseases and acute urinary tract infection.

Design outcomes

Primary

MeasureTime frame
uric acid;

Countries

China

Contacts

Public ContactLi Xiaoe

Weishan People's Hospital

xeli66@163.com+86 0537 8222216

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026